RIVA-VENLAFAXINE XR CAPSULE (EXTENDED RELEASE)

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE)

可用日期:

LABORATOIRE RIVA INC.

ATC代码:

N06AX16

INN（国际名称）:

VENLAFAXINE

剂量:

150MG

药物剂型:

CAPSULE (EXTENDED RELEASE)

组成:

VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 150MG

给药途径:

ORAL

每包单位数:

100/500

处方类型:

Prescription

治疗领域:

SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS

產品總結:

Active ingredient group (AIG) number: 0131294005; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2019-11-08

产品特点

_RIVA-VENLAFAXINE XR - Product Monograph _
_Page 1 of 71 _
PRODUCT MONOGRAPH
PR
RIVA-VENLAFAXINE XR
(venlafaxine hydrochloride extended release capsules)
venlafaxine (as venlafaxine hydrochloride)
USP
37.5 mg, 75 mg and 150 mg
Antidepressant / Anxiolytic
www.labriva.com
Submission Control No.: 240095
J7C 3V4
Blainville, Québec
660
Boul.
Industriel
LABORATOIRE RIVA INC.
July 8,
2020
Date of Revision:
_RIVA-VENLAFAXINE XR - Product Monograph _
_Page 2 of 71 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT
INFORMATION.........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
....................................................................................................
5
WARNINGS AND PRECAUTIONS
..................................................................................
6
ADVERSE REACTIONS
..................................................................................................
20
DRUG INTERACTIONS
..................................................................................................
37
DOSAGE AND ADMINISTRATION
..............................................................................
44
OVERDOSAGE
.................................................................................................................
48
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 49
STORAGE AND STABILITY
..........................................................................................
52
SPECIAL HANDLING INSTRUCTIONS
........................................................................
53
DOSAGE FORMS, COMPOSITION AND
PACKAGING.............................................. 53
PART II: SCIENTIFIC INFORMATION
................................................................................
54
PHARMACEUTICAL INFORM